Welcome to our dedicated page for Carlsmed news (Ticker: CARL), a resource for investors and traders seeking the latest updates and insights on Carlsmed stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Carlsmed's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Carlsmed's position in the market.
Carlsmed (NASDAQ:CARL), a commercial-stage medical technology company focused on AI-enabled personalized spine surgery solutions, has announced the pricing of its initial public offering. The company is offering 6.7 million shares at $15.00 per share, with trading expected to begin on July 23, 2025, on the Nasdaq Global Select Market.
The IPO is anticipated to generate gross proceeds of approximately $100.5 million before deducting underwriting costs and other expenses. Underwriters have a 30-day option to purchase up to an additional 1,005,000 shares. BofA Securities, Goldman Sachs & Co. LLC, and Piper Sandler are serving as joint lead book-running managers, with Truist Securities and BTIG acting as joint book-runners.
Carlsmed (NASDAQ:CARL), a commercial-stage medical technology company specializing in AI-enabled personalized spine surgery solutions, has announced its initial public offering. The company plans to offer 6.7 million shares of common stock with an expected price range of $14.00 to $16.00 per share.
The underwriters will have a 30-day option to purchase up to 1,005,000 additional shares. BofA Securities, Goldman Sachs & Co. LLC, and Piper Sandler are serving as joint lead book-running managers, while Truist Securities and BTIG are acting as joint book-runners. The company has applied to list on the Nasdaq Global Select Market under the ticker symbol "CARL".
